Current aspects of anticoagulant therapy for COVID-19

Автор: Kosimov U.M., Ergasheva M.M.

Журнал: Экономика и социум @ekonomika-socium

Рубрика: Основной раздел

Статья в выпуске: 1-1 (92), 2022 года.

Бесплатный доступ

COVID-19 is a severe and yet poorly understood infection that can affect almost all organs. The main target is the cells of the upper respiratory tract and alveolar tissue, which leads to the development of pneumonia and its complications. A decrease in these indicators is a poor prognostic sign. In addition, there may be an increase in ESR (erythrocyte sedimentation rate) and the number of platelets - cells that are responsible for blood clotting. Decreased platelet levels are less common.

Anticoagulants, antiaggregants, blood-thinning drugs, coronavirus infection, leukocytes, lymphocytes

Короткий адрес: https://sciup.org/140292601

IDR: 140292601

Статья научная